SAINT® Neuromodulation System to Treat Major Depressive Disorder in Adolescents

Ian A Cook MD¹, David M Carreon MD²; Hugh B Solvason MD³; Robert Bota MD⁵; Owen S Muir MD⁶; Carlene MacMillan MD^{6,7}; Rebecca M Allen MD⁸; Katy H Stimpson PhD⁹; Michael Feyder PhD⁹; TJ Ford BA⁹; Nabil Alnajjar MD⁹; Nolan R Williams MD¹⁰; Brandon S Bentzley MD PhD⁹.

¹Los Angeles TMS, Los Angeles, CA; ²Acacia Clinics, Sunnyvale, CA; ³Integral TMS, Sunnyvale, CA; ³Integral TMS, Sunnyvale, CA; ³Integral TMS, Sunnyvale, CA; ⁴Brain Health Solutions, Costa Mesa, CA; ³Integral TMS, Sunnyvale, CA; ⁴Brain Health Solutions, Costa Mesa, CA

Background

Saint

Approximately 20% of adolescents in the U.S. have experienced a major depressive episode (MDE) with 40% being diagnosed with treatment-resistant depression (TRD), increasing suicide risk. This necessitates effective and rapid treatment options for this vulnerable population. SAINT® is a functional connectivity-guided, accelerated form of intermittent theta burst (iTBS) transcranial magnetic stimulation.

SAINT has shown high and rapid remission rates in open-label and controlled trials in adults with TRD;¹⁻³ however, the effectiveness of SAINT for treating TRD in adolescents is otherwise unknown. We ventured to evaluate the efficacy of SAINT in treating adolescents as part of an ongoing open-label, multicenter trial.

Adolescents with moderate treatment-resistant depression treated with SAINT NMS experienced significant antidepressant response and decreased suicidal ideation immediately post-treatment.

Results

MADRS

13 adolescent participants (4 male, 9 female) were enrolled and completed the 5 day course of SAINT. Participants had a mean MADRS score of 19.2 baseline indicating moderate to severe depression; post-treatment mean MADRS scores dropped to 12.8. 69.2% of participants experienced remission and 92.3% experienced a response at either cessation of stimulation or 5 days post-treatment.

Suicidality: baseline vs. 5 days post

Methods

Seven clinical sites across the US participated in this trial.


Inclusion Criteria: • Ages 18-21 Primary MDD diagnosis without psychotic features • ≥1 failed antidepressant medication trial in current depressive episode Not pregnant or planning to become pregnant during acute treatment

Exclusion Criteria: Contraindication to TMS Contraindication to fMRI • Participants with an abnormal brain MRI as determined by PI, study physician or desig-• High risk of suicide or suicide attempt in last 6 months


All participants received a 5-day course of SAINT via the **SAINT** Neuromodulation System (NMS) which consists of: MagVenture MagPro X100 stimulator (MagVenture A/S, Denmark); MagVenture C-B60 and Cool-B65 coils; Localite neuronavigation system (Localite GmbH Sankt Augustin, Germany); and Magnus Cloud (Magnus Medical Inc., U.S.) for functional target generation. The SAINT protocol was administered according to previously published parameters¹.

The primary outcome was the Clinical Global Impressions Scale of Improvement (CGI-I) score following the final treatment session. Secondary outcome measures included the Montgomery Asberg Depression Rating Scale (MADRS) rated immediately post-treatment and the CGI-S to measure symptom severity. MADRS Item 10 was used for specific assessment of suicidal ideation.

MADRS: baseline vs. 5 days post



Response and remission: immediate post



MADRS Item 10: Suicidal Thoughts

Representing the feeling that life is not worth living, that a natural death would be welcome, suicidal thoughts, and preparations for suicide. Suicidal attempts should not in themselves influence the rating.

0 Enjoys life or takes it as it comes.

2 Weary of life. Only fleeting suicidal thoughts.

4 Probably better off dead. Suicidal thoughts are common, and suicide is considered as a possible solution, but without specific plans or intention.

6 Explicit plans for suicide when there is an opportunity. Active preparation for suicide.

Conclusion

These preliminary findings indicate that a 5-day course of SAINT


Figure 1: At baseline, participants had a mean MADRS score of 19.9 (SD=6.09). The mean MADRS score 5 days post-treatment was 12.8 (SD=5.46) across all included participants (n=13, paired t-test; p=0.0068, 95% CI [2.38, 11.93]) indicating a mean decrease of 35.9%. Cohen's d=0.905 indicating large effect size.

Figure 2: At baseline, participants who endorsed suicidal ideation had a mean MADRS item 10 score of 1.77 (SD=1.17). The mean suicidal ideation metric (MADRS item 10 score) 5 days post-treatment was 0.846 (SD=0.89) across all included participants (n=13, paired t-test; p=0.0268, 95% CI [0.13, 1.72]), a mean decrease of 52.1% from baseline. Cohen's d=0.699 indicating moderate effect size.


Immediate Post

Figure 3: 69.2% of participants were in remission at cessation of stimulation or at 5 days post-treatment. 92.3% of participants were in response at cessation of stimulation or at 5 days post-treatment. Remission was defined as MADRS ≤ 10 or a CGI-I score \leq 2. Response was defined as a decrease in MADRS by at least 50% or a CGI-I score of \leq 3.

Response rates over 12 months



Remission rates over 12 months



can provide rapid and significant improvements in depression symptoms in an adolescent population, warranting larger clinical trials. Due to the trial being ongoing, data for long-term outcomes is limited. Yet, data from the first participants to complete the 12 month timepoint suggests that response and remission rates carried throughout the 12 months of follow-up. A significant decrease in suicidality was also observed in this cohort immediately following treatment, holding potential for SAINT to be an effective, rapid-acting tool for treating suicidal ideation in this vulnerable population.



Figure 4: At the end of treatment day 5, the mean CGI-I score was 0.839 (n=13), an 84.6% response rate. Available long-term follow-up data shows sustained response across all timepoints with response rates of 90.9% (n=11) at 5 days post-treatment, 50% (n=6) at 1 month post, 88.9% (n=9) at 3 months post, 71.4% (n=7) at 6 months post,100% (n=5) at 9 months post, and 100% (n=2) at 12 months post.



Figure 5: At the end of treatment day 5, the mean CGI-I score was 0.839 (n=13), a 61.5% remission rate. Available long-term follow-up data shows sustained remission across all timepoints with remission rates of 45.45% (n=11) at 5 days post-treatment, 50% (n=6) at 1 month post, 66.7% (n=9) at 3 months post, 57.14% (n=7) at 6 months post, 80% (n=5) at 9 months post, and 50% (n=2) at 12 months post.

References	Disclosures	
1. Cole EJ, Stimpson KH, Bentzley BS, et al. Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. Am J Psychiatry. 2020;177(8):716-726. doi:10.1176/appi.ajp.2019.19070720 2. Williams NR, Sudheimer KD, Bentzley BS, et al. High-dose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression. Brain J Neurol. 2018;141(3):e18. doi:10.1093/brain/awx3792. 3. Cole EJ, Phillips AL, Bentzley BS, et al. Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. Am J Psychiatry. 2022;179(2):132-141. doi:10.1176/appi.ajp.2021.20101429 <i>ClinicalTrials.Gov registration</i> : NCT05819021 This trial was approved by Advarra IRB (IRB#00000971).	This trial was sponsored by Magnus Medical Inc. Dr. Williams and Dr. Bentzley are co-founders of Magnus Medical Inc. and in- ventors of affiliated intellectual property. Dr. Williams sits on the board of Magnus Medical with both equity and stock options; Dr. Bentzley is a salaried employee with equity and stock options. Katy H. Stimpson, Mike Feyder, TJ Ford, are salaried employ- ees with equity and stock options at Magnus Medical Inc.	